Alternative splicing of vascular calcification: Insights, opportunities, and challenges

Yingkun Sheng1, Hewen Wei2, Shengmin Lu3

  • 1Xingzhi College, Zhejiang Normal University, Jinhua 321100, China.

Cellular Signalling
|January 28, 2025
PubMed

Insights

Vascular calcification (VC) is a reversible condition linked to heart issues. Alternative splicing (AS) offers potential as biomarkers for early VC diagnosis and monitoring.

Area of Science:

  • Biomedical research
  • Cardiovascular science
  • Molecular biology

Background:

  • Vascular calcification (VC) is a significant risk factor for cardiovascular events, including myocardial infarction and sudden cardiac death.
  • VC contributes to cardiac and arterial thickening, leading to conditions like coronary heart disease and heart failure.
  • Despite being reversible, current clinical practices lack effective treatments to fully reverse or cure VC.

Purpose of the Study:

  • To explore the role of alternative splicing (AS) in vascular calcification (VC).
  • To highlight the potential of AS isoforms as biomarkers for early diagnosis and disease monitoring of VC.
  • To provide insights into novel diagnostic and therapeutic strategies for VC.

Main Methods:

  • Review of current literature on vascular calcification.
  • Analysis of the role of alternative splicing in cardiovascular diseases.
  • Identification of potential biomarker isoforms related to VC.

Main Results:

  • Alternative splicing (AS) presents extensive potential for clinical applications, including disease diagnosis and therapeutic targeting.
  • Different isoforms resulting from AS may serve as crucial indicators for VC.
  • Understanding AS isoforms can aid in developing new diagnostic and therapeutic approaches for VC.

Conclusions:

  • Early diagnostic markers for vascular calcification (VC) are crucial for improving patient outcomes.
  • Alternative splicing (AS) isoforms show promise as valuable biomarkers for the early detection and monitoring of VC.
  • Further research into AS in VC could lead to significant advancements in clinical management and treatment strategies.